Table III.
Complementary therapies and local responses.
| Case | Combination | Response | CEA1, ng/ml | CEA2, ng/ml |
|---|---|---|---|---|
| 1 | TDM-1 | PR | 8.1 | 5.1 |
| 2 | mTOR, PTX+BV | PD | 292.8 | 209.8 |
| 3 | (-) | SD | 3.6 | 4.5 |
| 4 | mTOR, Erib., PTX+BV | PD | 115.1 | 262.7 |
| 5 | (-) | PD | 12.9 | 45.1 |
| 6 | mTOR | PD | 145.5 | 624.8 |
| 7 | irradiation | PR | 3.7 | 3.8 |
| 8 | (-) | SD | 3.2 | 3.5 |
| 9 | AI, Fulvestrant | SD | 3.9 | 4.0 |
| 10 | (-) | PR | 10.6 | 2.1 |
mTOR, mammalian target of rapamycin; TDM-1, Trastuzumab emtansine; Erib, Eribulin; PTX, Pacritaxel; BV, Bevasitsuzumab; AI, Aromatase inhibitor; PR, partial remission; SD, stable disease; PD, progressive disease; CEA, Carcinoembryonic antigen; (-), no combination therapy.